WHO guidance · 2023
ADHD medicines: what WHO says
Wondering what WHO actually says about ADHD medication? This page stays within its guidance for children and adolescents—not adult prescribing.
Clairemind editorial summary · Sources checked 19 October 2026 · Not personal medical advice.
What does WHO recommend?
WHO’s 2023 mhGAP guidance says methylphenidate may be considered for children aged six and over and adolescents diagnosed with ADHD when symptoms still cause persistent, significant impairment in at least one area of functioning after environmental modifications.
WHO describes this recommendation as conditional, with low-certainty evidence. “May be considered” does not mean everyone should take it.
What conditions apply?
WHO calls for careful assessment, information for the child or adolescent and their caregivers about the options, and support in shared decision-making. Methylphenidate should be prescribed by, or in consultation with, a specialist.
Ask the treating clinician how the full recommendation applies to the young person’s circumstances. A website or screening score cannot make this decision.
Does this recommendation apply to adults?
No adult recommendation is made in this WHO guidance. This page does not extend its recommendation to adults or children under six. It is not a list of every ADHD medicine, and it gives no dose, medicine comparison or personal prescribing advice.
A question for the care team
You could ask: “Which guidance applies to this age group, and what should we understand about the options and uncertainty?” Read WHO’s full wording with the clinician rather than using this summary to make a medicine decision.
Read WHO’s full recommendation
WHO: interventions for children with ADHD ↗